Do the Pretransplant Use of Statins in a Recipient Reduce the Incidence of Primary Graft Dysfunction after Lung Transplant?

Primary graft dysfunction (PGD) is the main cause of mortality during the first month and the second one within the first year after lung transplantation (LT). Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been proposed as an effective class of drugs to reduce serum cholesterol levels due to their immunomodulatory and anti-inflammatory effects unrelated to their cholesterol-lowering function. We hypothesized that preoperative statin therapy is associated with decreased incidence of PGD after LT.

Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: I. Bello, E. Coll, A. Sandiumenge, L. Romero, A. Jauregui, J. P érez, J. Ochoa, S. Peñafiel, L. Sánchez, F. Ascanio, M. Montoya, E. San Ginés, J. Sacanell, C. Berastegui, C. Vázquez, I. Los Arcos, M. Deu Tags: 544 Source Type: research